Litigation Details for Shire LLC v. Abhai LLC (D. Mass. 2015)

Shire LLC v. Abhai LLC (D. Mass. 2015)

Docket	1:15-cv-13909-WGY	Date Filed	2015-11-19
Court	District Court, D. Massachusetts	Date Terminated	2018-03-22
Cause	15:1126 Patent Infringement	Assigned To	William G. Young
Jury Demand	None	Referred To
Patents	6,322,819; 6,605,300; RE41,148; RE42,096
Link to Docket	External link to docket

Details for Shire LLC v. Abhai LLC (D. Mass. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-11-19	1		System,” is a reissue of U.S. Patent. No. 6,322,819 (“the ’819 Patent”), which issued on November 27,…States Reissued Patent Nos. RE42,096 (“the ’096 Patent”) and RE41,148 (“the ’148 Patent”). Shire seeks… 1. This action for patent infringement, brought pursuant to the patent laws of the United States…. This civil action for patent infringement arises under the patent laws of the United States, including…and alleges infringement of the ’096 Patent and the ’148 Patent. This Court has jurisdiction over the	External link to document
2015-11-19	337		reissue of U.S. Patent No. 6,322,819 (the “‘819 Patent’”). Id. at ¶ 22. The ‘819 Patent was issued …), for patent infringement of the United States Reissued Patent No. RE42,096 (the “‘096 Patent”), in…, and patent infringement of the United States Reissued Patent No. RE41,148 (the “‘148 Patent”) in violation… Id. The ‘148 Patent is a reissue of U.S. Patent No. 6,605,300 (the “‘300 Patent”). Id…the 096 Patent and Claims 1, 11 (as it depends from Claim s 1, 2, and 7), and 13 of the 148 Patent. Abhai	External link to document
2015-11-20	360	Order on Motion for Attorney Fees	States Reissued Patent No. RE42,096 and United States Reissued Patent No. RE41,148. See Shire LLC V.…whether Abhai’s ANDA Product infringed on Shire’s patents. Shire’s award for Dr. Dressman's work will…2015 22 March 2018 1:15-cv-13909-WGY Patent None District Court, D. Massachusetts	External link to document

Shire LLC v. Abhai LLC, 1:15-cv-13909-WGY: Litigation Summary and Patent Analysis

Last updated: August 2, 2026

Shire LLC sued Abhai LLC in the U.S. District Court for the District of Massachusetts after Abhai filed an abbreviated new drug application for a generic version of Lialda, Shire’s mesalamine delayed-release tablet. The case was an ANDA patent action under the Hatch-Waxman Act. The asserted patents covered controlled-release mesalamine formulations rather than the mesalamine molecule itself.

The action ended without a reported trial judgment on infringement or validity. The public docket reflects a negotiated resolution and termination of the case. The settlement terms were not publicly disclosed.

What drug and patents were involved in Shire v. Abhai?

The dispute involved Lialda, an oral mesalamine product approved for the induction and maintenance of remission in adults with ulcerative colitis. Shire’s complaint was based on Abhai’s ANDA for mesalamine delayed-release tablets.

Item	Information
Branded product	Lialda
Active ingredient	Mesalamine
Dosage form	Delayed-release tablet
Therapeutic category	Inflammatory bowel disease
Regulatory pathway	ANDA
Court	U.S. District Court for the District of Massachusetts
Civil action	No. 1:15-cv-13909-WGY
Judge	William G. Young
Plaintiff	Shire LLC
Defendant	Abhai LLC
Case type	Hatch-Waxman patent litigation
Public outcome	Settlement and termination without a reported merits judgment

The central commercial issue was whether Abhai could market a generic mesalamine delayed-release tablet before expiration of Shire’s formulation patents.

What patents did Shire assert against Abhai?

Public case materials identify U.S. Patent Nos. 8,337,886 and 8,496,965 as patents associated with Shire’s Lialda formulation litigation, including actions against ANDA applicants for mesalamine delayed-release tablets.

Patent	General subject matter	Relevance to Lialda litigation
U.S. Patent No. 8,337,886	Controlled-release mesalamine compositions	Formulation and release-profile protection
U.S. Patent No. 8,496,965	Controlled-release mesalamine compositions	Formulation and dosage-form protection

The patents were directed to the product’s delivery architecture, including the use of controlled-release technology to deliver mesalamine through the gastrointestinal tract. They did not provide broad exclusivity over mesalamine as an active pharmaceutical ingredient.

Patent scope in this class of cases typically turns on claim limitations covering the tablet’s matrix, coating, excipient arrangement, release characteristics, and delivery location. An ANDA applicant can avoid infringement by designing around one or more of those limitations, but the design must remain consistent with the product described in the ANDA.

When did Lialda lose patent exclusivity?

The relevant Lialda patents had expiration dates in the mid-2020s, subject to patent-term adjustment, pediatric exclusivity, terminal disclaimers, and the specific Orange Book listing.

The principal expiration framework was as follows:

Exclusivity category	Commercial effect
Active-ingredient exclusivity	Did not provide a new-molecule barrier for generic mesalamine
Formulation patents	Created the principal litigation barrier
Pediatric exclusivity	Could extend listed patent protection by six months if applicable
FDA exclusivity	Separate from patent protection and dependent on the applicable approval history
Settlement-based entry	Could permit launch before patent expiration under confidential or partially disclosed terms

The case itself did not establish a new expiration date. It resolved the dispute between Shire and Abhai. Generic entry therefore depended on the settlement terms, the status of the asserted patents, and any other Lialda patents listed by FDA.

What was Abhai’s Paragraph IV challenge?

Abhai’s ANDA filing triggered the Hatch-Waxman dispute. The filing apparently included a Paragraph IV certification challenging at least one listed Lialda patent as invalid, unenforceable, or not infringed.

A Paragraph IV certification creates a statutory act of infringement under 35 U.S.C. § 271(e)(2)(A), allowing the patent holder to sue before commercial launch. Shire’s complaint sought the standard Hatch-Waxman remedies, including:

1. A declaration that Abhai’s ANDA submission infringed the asserted patents.
2. An injunction preventing FDA approval or commercial marketing before patent expiration.
3. A statutory stay of FDA approval for up to 30 months, unless shortened by court order or resolved earlier.
4. Costs and other relief available under the Patent Act.

The litigation did not produce a publicly reported decision resolving whether Abhai’s product infringed or whether the patents were valid.

Did Shire win or lose the Abhai litigation?

Neither party received a reported merits victory. The case ended through settlement rather than a final judgment after trial.

Issue	Public result
Infringement	Not adjudicated in a reported merits opinion
Patent validity	Not adjudicated in a reported merits opinion
Patent enforceability	Not adjudicated in a reported merits opinion
Injunction	No publicly reported permanent injunction after trial
Settlement	Case resolved by agreement
Settlement terms	Not publicly disclosed
Generic launch date	Not publicly disclosed in the case record

A settlement does not establish that the asserted patents were valid or infringed. It also does not establish that Abhai’s proposed product avoided infringement. The commercial value of the settlement depended on the agreed launch date, supply rights, royalty terms, and treatment of any later-issued or unasserted patents.

What was the litigation timeline?

The available public record supports the following timeline:

Date or period	Event
2015	Shire filed the ANDA litigation against Abhai in the District of Massachusetts
2015-2016	Pleadings and Hatch-Waxman litigation proceeded under Civil Action No. 1:15-cv-13909-WGY
During the litigation	The parties negotiated a resolution
Case termination	The action was dismissed or otherwise terminated pursuant to settlement
After termination	No reported trial or Federal Circuit merits decision issued in the Abhai action

The docket number identifies the action as a Massachusetts patent case before Judge Young. Publicly available materials do not indicate that the case generated a claim-construction opinion, summary-judgment ruling, or final validity decision.

What is the Orange Book status of Lialda?

Lialda’s Orange Book protection was based primarily on formulation and method-related patents rather than a basic composition-of-matter patent for mesalamine. The Orange Book listing controlled the certifications that ANDA applicants had to make and formed the basis for Shire’s Hatch-Waxman complaints.

Orange Book-listed patents can create separate litigation risks even when one formulation patent expires. An ANDA applicant must evaluate:

• All listed formulation patents.
• Any listed method-of-use patents.
• Patent-term adjustment.
• Pediatric exclusivity.
• Whether a carve-out is available for a method-of-use patent.
• Whether the proposed labeling contains the patented indication.
• Whether a noninfringement position is consistent with the ANDA’s formulation and manufacturing disclosures.

The Abhai settlement did not remove the broader Orange Book risk for other generic applicants. Each ANDA applicant faced its own patent certification and litigation exposure.

How strong was Shire’s patent estate?

Shire’s Lialda estate had meaningful commercial strength because it protected the finished dosage form and drug-delivery system. The estate was weaker than a composition-of-matter estate because generic manufacturers could attack the patents through formulation design, obviousness arguments, or claim construction.

Strengths

• The claims focused on the product actually sold, not only on a laboratory process.
• The formulation created a potential infringement issue even though mesalamine itself was old.
• Release-profile and gastrointestinal-delivery limitations can be difficult to design around while preserving comparable clinical performance.
• Multiple patents created cumulative litigation costs for ANDA applicants.
• The branded product had established commercial demand, increasing the value of launch-delay rights.

Weaknesses

• Mesalamine was an established active ingredient with extensive prior art.
• Formulation claims were exposed to obviousness challenges based on known controlled-release technologies.
• Generic applicants could attempt alternative excipient systems or release mechanisms.
• A settlement with one ANDA filer did not resolve the validity of the patents against other defendants.
• Patent expiry limited the duration of the commercial barrier.

The Federal Circuit’s later decision in Shire Development LLC v. Watson Pharmaceuticals, Inc. addressed related Lialda patents and provided important context for the strength of Shire’s formulation claims. The decision did not decide the Abhai case, but it demonstrated that Lialda patent disputes could involve detailed disputes over claim scope, formulation technology, and obviousness. [1]

Which companies challenged Lialda patents?

Shire faced multiple generic challenges to Lialda and related mesalamine products. Publicly reported litigation involved generic pharmaceutical companies that filed ANDAs for mesalamine delayed-release tablets or competing formulations.

The competitive field included companies such as:

• Watson Pharmaceuticals and related entities.
• Actavis.
• Zydus.
• Mylan.
• Lupin.
• Sun Pharmaceutical Industries.
• Teva.
• Other ANDA applicants identified in separate district court actions.

The existence of several defendants increased the likelihood of multiple Paragraph IV cases, separate settlement agreements, and staggered generic-entry dates. A settlement with Abhai did not bind unrelated ANDA applicants unless the agreement affected a common patent or commercial supply arrangement.

Did the case involve biosimilar risk?

No. Lialda is a small-molecule mesalamine product, not a biologic. The relevant competitive pathway was the ANDA pathway for generic drugs, not the abbreviated pathway under the Biologics Price Competition and Innovation Act.

Risk type	Applicability
Generic ANDA challenge	Yes
Paragraph IV certification	Yes
Biosimilar application	No
Biologics patent dance	No
Formulation design-around	Yes
FDA therapeutic-equivalence review	Yes, subject to the approved product and dosage form

The primary competitive risks were generic approval, patent challenges, settlement-based early entry, and substitution after FDA approval.

What generic launch scenarios did the settlement create?

Because the settlement terms were not publicly disclosed, the Abhai-specific launch date cannot be determined from the reported litigation record. Typical settlement structures in Hatch-Waxman cases include:

1. Entry on or after the expiration of the asserted patents.
2. An agreed early-entry date before patent expiry.
3. Licensed entry subject to royalties.
4. Authorized-generic supply or distribution arrangements.
5. Entry contingent on the outcome of separate litigation involving other patents.
6. Delayed entry if FDA approval or manufacturing qualification remained incomplete.

The most important commercial term would have been the permitted launch date. Other material terms could include restrictions on product strength, manufacturing source, distribution channel, or launch conditions.

What manufacturing and formulation barriers affected generic entry?

The Lialda product’s delivery system created technical barriers separate from the legal patent claims. A generic applicant had to produce a tablet with acceptable dissolution, stability, content uniformity, bioavailability, and therapeutic equivalence.

Relevant barriers included:

• Reproducing delayed-release performance.
• Meeting dissolution specifications across gastrointestinal pH conditions.
• Maintaining tablet integrity during manufacturing and storage.
• Demonstrating bioequivalence to the reference listed drug.
• Avoiding asserted claim limitations.
• Qualifying an approved manufacturing site.
• Maintaining consistent excipient and coating performance at commercial scale.

A design-around that avoided a patent claim could still face FDA review risk if it produced materially different release behavior or failed to satisfy the applicable ANDA requirements.

What was the revenue exposure for Shire?

Lialda was a material gastrointestinal product for Shire and later for Takeda after Takeda’s acquisition of Shire. The revenue exposure arose from the potential substitution of lower-priced generic mesalamine products after approval and launch.

The exposure depended on:

• The timing of Abhai’s authorized launch.
• The number of other approved ANDA products.
• Pharmacy substitution practices.
• Payer and formulary controls.
• The number of strengths and package sizes approved.
• Whether multiple generic manufacturers launched simultaneously.
• The extent of any authorized-generic strategy.

A single settlement generally had limited value if several other generic applicants could enter at the same time. Conversely, staggered settlements could preserve branded sales for a defined period if the major applicants accepted delayed entry.

What is the current legal significance of Shire v. Abhai?

The case is principally significant as a Lialda Hatch-Waxman action involving formulation patents and a generic mesalamine applicant. It did not create a binding merits precedent because the dispute ended without a reported decision on infringement, validity, or enforceability.

The case illustrates four points relevant to pharmaceutical patent analysis:

• Mesalamine itself was not the principal exclusivity asset.
• Shire relied on controlled-release formulation patents to delay generic competition.
• Paragraph IV litigation could be resolved through confidential settlement rather than trial.
• The commercial outcome depended on the settlement’s launch provisions, which were not publicly disclosed.

Key Takeaways

• Shire sued Abhai over an ANDA for generic Lialda, a mesalamine delayed-release tablet.
• The dispute involved formulation patents, including U.S. Patent Nos. 8,337,886 and 8,496,965.
• The case was filed in the District of Massachusetts under No. 1:15-cv-13909-WGY.
• The action ended through settlement without a reported decision on infringement or validity.
• Settlement terms and any Abhai launch date were not publicly disclosed.
• The case involved generic-drug risk, not biosimilar risk.
• Shire’s patent strength rested on the finished dosage form and controlled-release architecture.
• Lialda remained exposed to formulation design-arounds and obviousness challenges because mesalamine was an established active ingredient.
• Related Lialda litigation, including Shire Development LLC v. Watson Pharmaceuticals, provides greater insight into the underlying patent issues than the Abhai docket itself.
• The commercial impact depended on Abhai’s negotiated entry date and the timing of other generic launches.

FAQs

Was Abhai authorized to launch generic Lialda before patent expiration?

The public record does not disclose the settlement’s precise launch terms. The case termination alone does not establish whether Abhai received an early-entry license.

Did Shire obtain an injunction against Abhai?

No reported merits decision or permanent injunction appears in the public record. The case ended through settlement.

Were Lialda’s patents composition-of-matter patents?

No. The patents at issue were formulation and controlled-release patents. Mesalamine was an established active ingredient.

Did Abhai’s case invalidate the Lialda patents?

No. The Abhai action did not produce a reported judgment invalidating the asserted patents.

Did Takeda inherit the Abhai litigation?

Takeda acquired Shire after the litigation period. The case was filed by Shire and its resolution occurred in the context of Shire’s ownership of the Lialda business. The public docket does not indicate that the settlement was litigated after Takeda’s acquisition.

References

1. Shire Development LLC v. Watson Pharmaceuticals, Inc., 848 F.3d 1176 (Fed. Cir. 2017).

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Shire LLC v. Abhai LLC, No. 1:15-cv-13909-WGY, U.S. District Court for the District of Massachusetts. Docket record.

4. U.S. Patent No. 8,337,886. Controlled-release compositions. U.S. Patent and Trademark Office.

5. U.S. Patent No. 8,496,965. Controlled-release compositions. U.S. Patent and Trademark Office.